The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
CYP3A4 protein results in increased metabolism of acalabrutinib Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of acalabrutinib]
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein]; afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]
afatinib results in decreased activity of EGFR protein; afatinib results in decreased activity of EGFR protein mutant form afatinib results in decreased phosphorylation of EGFR protein
afatinib results in decreased expression of POU5F1 protein afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]
1-(3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]; NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]
LGK974 inhibits the reaction [Paraquat affects the localization of CTNNB1 protein]; LGK974 inhibits the reaction [Paraquat results in increased expression of and results in decreased phosphorylation of CTNNB1 protein]
marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of AREG protein]; marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein]
DRD2 promoter polymorphism affects the susceptibility to nemonapride Cinnarizine inhibits the reaction [nemonapride binds to DRD2 protein]; Flunarizine inhibits the reaction [nemonapride binds to DRD2 protein]
[4-amylcinnamoylanthranilic acid results in decreased activity of SLC13A2 protein] which results in decreased susceptibility to diethylene glycol metabolite
4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] 4-amylcinnamoylanthranilic acid results in decreased activity of TRPM2 protein
N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]; N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein]
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein]
ABCB1 protein affects the susceptibility to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased abundance of and results in increased secretion of Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Paclitaxel]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine]
ABCG2 protein affects the susceptibility to 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein results in increased phosphorylation of ABL1 protein]; [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of ABL1 protein 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of ABL1 protein mutant form
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased phosphorylation of ACACA protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ALDH1A2 mRNA
[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of AP2M1 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ATF6 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of BAX protein] 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of BAX mRNA]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of BAX protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of BCL2 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of BCR protein mutant form
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of C3 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of CASP3 mRNA]; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of CASP3 protein] 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of CASP3 protein 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of CASP3 protein] benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP3 protein] 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased activity of CASP3 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased activity of CASP7 protein 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP7 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of CASP9 protein
[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of CLTC mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased phosphorylation of CRKL protein 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABL1 protein mutant form results in increased phosphorylation of CRKL protein]; [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide co-treated with arsenic trioxide] results in decreased phosphorylation of CRKL protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of DDIT3 mRNA arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of DDIT3 mRNA]
[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of DNM2 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of EDEM1 mRNA arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of EDEM1 mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of ESR1 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of EYA1 mRNA
[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of FCER1G mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS protein arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of FOS protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of FOXC2 mRNA
arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of GCLM mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased secretion of GPT protein 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased activity of GPT protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased activity of GSR protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of HDC mRNA 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of HMOX1 mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HOXB7 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HOXB9 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HSPA5 mRNA arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of HSPA5 mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of IL18 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of IL1B protein] 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of IL1B protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of IL2 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in increased expression of IL6 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of and results in increased phosphorylation of JUN protein; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN protein] 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUN protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB mRNA; 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB protein arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB mRNA]; arsenic trioxide promotes the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of JUNB protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased activity of KCNH2 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of MEOX1 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of MESP2 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of NEUROG2 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of NFE2L2 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Cyclosporine results in decreased expression of NFKBIA mRNA]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of OLIG3 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased cleavage of PARP1 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of PAX3 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of PAX6 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of RELA protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of SACS mRNA
[arsenic trioxide co-treated with 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide] affects the expression of SEC24B mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of TCF15 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of TFF1 mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA] 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of TNF protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [Folic Acid results in increased expression of TNFSF12 protein]
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased secretion of TP53 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased activity of UGT1A1 protein
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in decreased expression of UNCX mRNA
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide results in increased expression of XBP1 mRNA alternative form
osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; Vitamin E inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]
CAT protein inhibits the reaction [osimertinib results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form] CAT protein results in decreased susceptibility to osimertinib
osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]
osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]; osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein osimertinib results in decreased activity of EGFR protein
osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]
osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK1 protein
osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK3 protein
osimertinib results in increased expression of PARP1 protein modified form osimertinib results in increased cleavage of PARP1 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; [TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]; Vitamin E inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of STAT3 protein]
TWIST1 protein results in decreased susceptibility to osimertinib [TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein] TWIST1 protein affects the susceptibility to osimertinib
Barium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Diethyl Pyrocarbonate inhibits the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Ouabain promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]; Potassium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid]
SLC22A6 protein affects the transport of p-Aminohippuric Acid SLC22A6 protein results in increased import of p-Aminohippuric Acid SLC22A6 protein results in increased uptake of p-Aminohippuric Acid; SLC22A6 results in increased uptake of p-Aminohippuric Acid 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; 9-((2-phosphonylmethoxy)ethyl)guanine analog inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; adefovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Amitriptyline inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I inhibits the reaction [SLC22A6 results in increased uptake of p-Aminohippuric Acid]; aristolochic acid I promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; bis(4-hydroxyphenyl)sulfone inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol A promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; bisphenol F promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefaclor inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefdinir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cefotiam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftibuten inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Ceftizoxime inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cephaloridine inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Chlorides promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; chlorpyrifos-methyl inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Cimetidine inhibits the reaction [SLC22A6 protein affects the transport of p-Aminohippuric Acid]; cyazofamid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Diazepam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fenitrothion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Fluorescein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Glutarates promotes the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; glutaric acid promotes the reaction [SLC22A6 results in increased export of p-Aminohippuric Acid]; Malathion inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Mianserin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased susceptibility to [mercuric oxide co-treated with Acetylcysteine]]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid analog]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased transport of 2-amino-3-(2-amino-2-carboxyethylsulfanyl-mercuricsulfanyl)-propionic acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of 2,4-Dichlorophenoxyacetic Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Uric Acid]; Penicillin G inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Quercetin inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Resveratrol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; rhein metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Sulfobromophthalein inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; Triazolam inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Unithiol metabolite promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid]; Unithiol promotes the reaction [SLC22A6 protein results in increased secretion of p-Aminohippuric Acid] p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of ochratoxin A]; perfluoro-n-heptanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorohexanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]; perfluorooctanoic acid inhibits the reaction [SLC22A6 protein results in increased import of p-Aminohippuric Acid]
Cimetidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Enalapril inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; Ibuprofen inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid]; tenoxicam inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid] SLC22A8 protein affects the transport of p-Aminohippuric Acid SLC22A8 results in increased export of p-Aminohippuric Acid aristolochic acid I promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid]; estrone sulfate promotes the reaction [SLC22A8 results in increased export of p-Aminohippuric Acid] p-Aminohippuric Acid inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]
[TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA palmidrol results in decreased expression of CLDN3 mRNA
palmidrol binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]
[MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] palmidrol affects the localization of PPARA protein
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]
ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A [ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]
Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]
PD168393 results in increased expression of and results in increased secretion of CCL2 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]
acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; PD168393 results in increased expression of and results in increased secretion of CXCL10 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]
PD168393 affects the localization of EGFR protein; PD168393 affects the localization of EGFR protein modified form PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein] PD168393 results in decreased phosphorylation of EGFR protein
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK1 protein]; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein] PD168393 results in decreased phosphorylation of MAPK1 protein
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK3 protein]; PD168393 inhibits the reaction [resveratrol results in increased phosphorylation of MAPK3 protein] PD168393 results in decreased phosphorylation of MAPK3 protein
PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]
PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]
pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased cleavage of BID protein]
pepstatin affects the reaction [thallium nitrate results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased activity of CASP3 protein] [aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein modified form]
pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein modified form]
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSB protein
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSD protein; pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] pepstatin results in decreased activity of CTSD protein
[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of LAMP2 protein
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; pepstatin promotes the reaction [BO-1051 results in increased expression of MAP1LC3B protein modified form]
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of AKT1 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of BCL2L1 protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in decreased expression of CAT protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased activity of MET protein 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of and results in decreased activity of MET protein; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA; Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein] 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of XIAP protein
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]
salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of FN1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; salubrinal inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein]
[salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein; salubrinal inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of ATF4 protein]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of ATF4 protein]]; salubrinal promotes the reaction [Quercetin results in increased expression of ATF4 protein] salubrinal promotes the reaction [Thapsigargin results in increased expression of ATF4 protein]; salubrinal promotes the reaction [Tunicamycin results in increased expression of ATF4 protein] salubrinal promotes the reaction [Cisplatin results in increased expression of ATF4 protein] salubrinal results in increased expression of ATF4 protein
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased expression of BAX protein]]; salubrinal promotes the reaction [Cisplatin results in increased expression of BAX protein] salubrinal inhibits the reaction [cadmium acetate results in increased expression of BAX protein]
salubrinal inhibits the reaction [alpha-Tocopherol analog results in decreased expression of BCL2 protein]; salubrinal inhibits the reaction [Quercetin results in decreased expression of BCL2 protein] salubrinal inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]]; salubrinal promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]
salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased expression of BECN1 protein]
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP12 protein]]; salubrinal inhibits the reaction [decamethrin results in increased expression of CASP12 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of CASP12 mRNA]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP12 protein] salubrinal inhibits the reaction [arsenite results in increased activity of CASP12 protein]; salubrinal inhibits the reaction [Rotenone results in increased cleavage of CASP12 protein]
salubrinal inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; salubrinal inhibits the reaction [MAP3K5 protein results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Paraquat results in increased activity of CASP3 protein] salubrinal inhibits the reaction [Rotenone results in increased expression of CASP3 mRNA]; salubrinal inhibits the reaction [Tetrachlorodibenzodioxin results in increased cleavage of CASP3 protein] salubrinal inhibits the reaction [decamethrin results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [decamethrin results in increased cleavage of and results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of CASP3 mRNA]; salubrinal promotes the reaction [Cisplatin results in increased activity of CASP3 protein]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]
Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]]; salubrinal promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]
salubrinal inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]
salubrinal inhibits the reaction [Cyclosporine results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]
salubrinal inhibits the reaction [MAP3K5 protein affects the localization of CYCS protein]; salubrinal inhibits the reaction [Paraquat affects the localization of CYCS protein]
EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; salubrinal inhibits the reaction [2,3,5-trichloro-6-phenyl-(1,4)benzoquinone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Cadmium Chloride results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Quercetin results in increased expression of DDIT3 protein] salubrinal results in decreased expression of DDIT3 protein salubrinal inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Thapsigargin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Tunicamycin results in increased expression of DDIT3 protein] salubrinal results in increased expression of DDIT3 mRNA Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased expression of DDIT3 protein]]; salubrinal inhibits the reaction [alpha-naphthoflavone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Rotenone results in increased expression of DDIT3 protein]; salubrinal inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Cisplatin results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Cyclosporine results in increased expression of DDIT3 protein]; salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein]
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of EIF2A protein]; salubrinal inhibits the reaction [EIF2A protein results in decreased susceptibility to nonivamide] salubrinal results in increased expression of EIF2A protein modified form salubrinal results in increased phosphorylation of EIF2A protein salubrinal affects the phosphorylation of EIF2A protein Acetylcysteine inhibits the reaction [salubrinal promotes the reaction [Cisplatin results in increased phosphorylation of EIF2A protein]]; salubrinal promotes the reaction [Cisplatin results in increased phosphorylation of EIF2A protein]
salubrinal results in increased expression of EIF2S1 protein modified form salubrinal results in increased phosphorylation of EIF2S1 protein salubrinal inhibits the reaction [Rotenone results in decreased phosphorylation of EIF2S1 protein] [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK1 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK3 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK8 protein; [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK9 protein; salubrinal inhibits the reaction [cadmium acetate results in increased expression of EIF2S1 protein modified form]; salubrinal inhibits the reaction [Rotenone results in decreased phosphorylation of EIF2S1 protein]; salubrinal inhibits the reaction [Thapsigargin results in increased expression of EIF2S1 mRNA]; salubrinal inhibits the reaction [Tunicamycin results in increased expression of EIF2S1 mRNA]; salubrinal promotes the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of EIF2S1 protein] [salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein; [salubrinal results in decreased activity of EIF2S1 protein] which results in decreased susceptibility to decamethrin; EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of DDIT3 protein]]; EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased phosphorylation of EIF2S1 protein]]; salubrinal promotes the reaction [Cadmium Chloride results in increased phosphorylation of EIF2S1 protein]; salubrinal promotes the reaction [Paraquat results in increased expression of EIF2S1 protein modified form]; salubrinal promotes the reaction [Quercetin results in increased phosphorylation of EIF2S1 protein]; salubrinal results in increased phosphorylation of and results in decreased activity of EIF2S1 protein
[salubrinal co-treated with EPO protein] results in decreased expression of ATF4 protein; [salubrinal co-treated with EPO protein] results in increased phosphorylation of EIF2S1 protein
salubrinal inhibits the reaction [Thapsigargin results in decreased expression of HGF mRNA]; salubrinal inhibits the reaction [Thapsigargin results in decreased expression of HGF protein]; salubrinal inhibits the reaction [Tunicamycin results in decreased expression of HGF mRNA]; salubrinal inhibits the reaction [Tunicamycin results in decreased expression of HGF protein]
EIF2S1 protein promotes the reaction [salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [4-Quinolones analog inhibits the reaction [Glucose deficiency results in increased expression of HSPA5 protein]]; salubrinal inhibits the reaction [Paraquat results in increased expression of HSPA5 protein] salubrinal inhibits the reaction [Rotenone results in increased expression of HSPA5 protein] salubrinal results in increased expression of HSPA5 protein salubrinal inhibits the reaction [Rotenone results in increased expression of HSPA5 protein]; salubrinal inhibits the reaction [Tunicamycin results in increased expression of HSPA5 mRNA]; salubrinal promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of HSPA5 protein]
salubrinal affects the susceptibility to MAP3K5 protein salubrinal affects the susceptibility to [Paraquat co-treated with MAP3K5 protein]; salubrinal inhibits the reaction [MAP3K5 protein affects the localization of CYCS protein]; salubrinal inhibits the reaction [MAP3K5 protein results in increased activity of CASP3 protein]; salubrinal inhibits the reaction [Paraquat results in increased phosphorylation of and results in increased activity of MAP3K5 protein]; salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased expression of BECN1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased expression of BECN1 protein]
salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein] [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK1 protein
salubrinal inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein] [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK3 protein
[salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK8 protein salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of MAPK8 protein]; salubrinal inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein]
salubrinal inhibits the reaction [alpha-Tocopherol analog results in increased phosphorylation of MAPK9 protein] [salubrinal results in increased expression of EIF2S1 protein modified form] which results in increased phosphorylation of MAPK9 protein
salubrinal inhibits the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein]; salubrinal inhibits the reaction [Cyclosporine results in increased cleavage of PARP1 protein]
[salubrinal results in decreased activity of [PPP1CC protein binds to PPP1R15A protein]] which affects the localization of CALR protein salubrinal results in increased expression of PPP1R15A protein
salubrinal promotes the reaction [[Paraquat co-treated with MAP3K5 protein] results in increased degradation of SQSTM1 protein]; salubrinal promotes the reaction [MAP3K5 protein results in increased degradation of SQSTM1 protein]
salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; salubrinal inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA]
salubrinal inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; salubrinal inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; salubrinal inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein]
SCH772984 results in decreased secretion of ADM protein SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein]
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of and results in increased expression of CREB1 protein]; SCH772984 results in decreased phosphorylation of and results in decreased expression of CREB1 protein
SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 mRNA]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 protein]
SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein] SCH772984 results in increased secretion of FGF2 protein
[SCH772984 co-treated with bilobalide] inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; SCH772984 inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein]
SCH772984 results in increased phosphorylation of MAPK1 protein SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK1 protein] SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein] SCH772984 results in decreased expression of MAPK1 protein SCH772984 results in decreased activity of MAPK1 protein
SCH772984 results in decreased activity of MAPK3 protein SCH772984 results in decreased expression of MAPK3 protein SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK3 protein] SCH772984 results in increased phosphorylation of MAPK3 protein SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein]
SCH772984 results in decreased expression of MAPK8 protein SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK8 protein]
SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of and results in increased phosphorylation of SP1 protein]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of SP1 mRNA]
SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]
SR 144528 inhibits the reaction [Dronabinol results in decreased phosphorylation of AKT1 protein]; SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein]
SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 protein]]
SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]
SR 144528 binds to CNR2 protein SR 144528 binds to and results in decreased activity of CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog; SR 144528 binds to and results in decreased activity of CNR2 protein; SR 144528 inhibits the reaction [[3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo(c)chromen-6-one binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [[AM 1241 binds to and results in increased activity of CNR2 protein] which results in decreased susceptibility to Paclitaxel]; SR 144528 inhibits the reaction [CNR2 protein affects the susceptibility to Dronabinol] [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; SR 144528 binds to and results in decreased activity of CNR2 protein; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CCL2 protein]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CXCL8 mRNA]]; SR 144528 inhibits the reaction [CNR2 protein promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of CXCL8 protein]]; SR 144528 inhibits the reaction [Dronabinol inhibits the reaction [ERBB2 protein binds to CNR2 protein]]
SR 144528 inhibits the reaction [Dronabinol inhibits the reaction [ERBB2 protein binds to CNR2 protein]]; SR 144528 inhibits the reaction [Dronabinol inhibits the reaction [ERBB2 protein binds to ERBB2 protein]]; SR 144528 inhibits the reaction [Dronabinol results in decreased expression of and affects the phosphorylation of ERBB2 protein]
SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IFNG mRNA]; SR 144528 inhibits the reaction [Dronabinol results in decreased expression of IFNG protein]
SR 144528 inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]]
SR 144528 inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]]
[Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; SR 144528 inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]
SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL4 mRNA]; SR 144528 inhibits the reaction [Dronabinol results in increased expression of IL4 protein]
SR 144528 inhibits the reaction [Dronabinol results in decreased phosphorylation of MAPK1 protein]; SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK1 protein]
SR 144528 inhibits the reaction [Dronabinol results in decreased phosphorylation of MAPK3 protein]; SR 144528 inhibits the reaction [Dronabinol results in increased phosphorylation of MAPK3 protein]; SR 144528 inhibits the reaction [methanandamide results in increased phosphorylation of MAPK3 protein]
[Rimonabant co-treated with SR 144528] inhibits the reaction [OMDM-1 cpd inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
SR 144528 inhibits the reaction [Dronabinol results in increased localization of RAF1 protein]; SR 144528 inhibits the reaction [methanandamide results in increased localization of RAF1 protein]
SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of IRF1 protein]]; SR 144528 inhibits the reaction [caryophyllene inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]
SR 144528 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein]
Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]; Suramin inhibits the reaction [Clodronic Acid results in increased expression of CASP3]
Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of IL10 protein] Suramin results in decreased activity of IL10 protein
Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Silicon Dioxide analog results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK1 protein] Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein] Suramin inhibits the reaction [2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK3 protein] Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein] Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]
JTE 013 promotes the reaction [Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin promotes the reaction [JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein] Suramin results in increased expression of SHC1 mRNA; Suramin results in increased expression of SHC1 protein
Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein]; Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] [Suramin results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol
teriflunomide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]] teriflunomide results in decreased expression of DHODH mRNA teriflunomide inhibits the reaction [DHODH protein results in increased metabolism of 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone]; teriflunomide inhibits the reaction [DHODH protein results in increased metabolism of 4,5-dihydroorotic acid]; teriflunomide inhibits the reaction [DHODH protein results in increased metabolism of Ubiquinone]; teriflunomide inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]; teriflunomide inhibits the reaction [Ubiquinone affects the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]] teriflunomide results in decreased activity of DHODH protein
teriflunomide results in increased expression of G6PC1 mRNA Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC1 mRNA]
Cytidine inhibits the reaction [teriflunomide results in increased expression of GYPA protein]; Uridine inhibits the reaction [teriflunomide results in increased expression of GYPA protein]
Ceramides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Hydrogen Peroxide inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Lipopolysaccharides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Okadaic Acid inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]; Tetradecanoylphorbol Acetate inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]
teriflunomide results in increased expression of PCK1 mRNA Colforsin inhibits the reaction [teriflunomide results in increased expression of PCK1 mRNA]
Ceramides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Hydrogen Peroxide inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Lipopolysaccharides inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; Okadaic Acid inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein affects the localization of RELA protein]; teriflunomide inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]]; Tetradecanoylphorbol Acetate inhibits the reaction [teriflunomide results in increased activity of [NFKB1 protein binds to RELA protein]]
teriflunomide inhibits the reaction [TNF protein affects the localization of RELA protein]; teriflunomide inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; teriflunomide inhibits the reaction [TNF protein results in increased activity of LCK protein]; teriflunomide inhibits the reaction [TNF protein results in increased activity of MAP2K1 protein]; teriflunomide inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; teriflunomide inhibits the reaction [TNF protein results in increased expression of [NFKB1 protein binds to RELA protein]] teriflunomide inhibits the reaction [Carbon Tetrachloride results in increased secretion of TNF protein]
AHR protein results in increased susceptibility to tranilast tranilast results in increased expression of AHR mRNA AHR protein promotes the reaction [tranilast results in increased expression of AHR mRNA]; AHR protein promotes the reaction [tranilast results in increased expression of CYP1A1 mRNA]; tranilast promotes the reaction [AHR protein binds to CYP1A1 promoter]
AHR protein promotes the reaction [tranilast results in increased expression of CYP1A1 mRNA]; tranilast promotes the reaction [AHR protein binds to CYP1A1 promoter]
Turphostin B42 decreased expression of Jak2 mRNA in myofibroblasts tyrphostin B42 inhibits the reaction [cisplatin increases expression of Jak2 mRNA in kidney] tyrphostin B42 inhibits the reaction [selumetinib increases phosphorylation of JAK2 protein in colonic epithelium] tyrphostin B42 decreases expression and phosphorylation of JAK2 protein in colonic epithelium tyrphostin B42 co-treated with N-acetyl-L-cysteine inhibits the reaction [Ginkgoic acid increases phosphorylation of JAK2 protein in stomach]
[nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of HOPX mRNA; [nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of HOPX protein
[nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of PDPN mRNA; [nitrofen co-treated with N,N'-bis(dichloroacetyl)-1,8-octamethylenediamine] results in decreased expression of PDPN protein
browse the term
